| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6933310 | MITSUBISHI TANABE | Therapeutic agent for amyotrophic lateral sclerosis (ALS) |
Nov, 2020
(3 years ago) | |
Radicava is owned by Mitsubishi Tanabe.
Radicava contains Edaravone.
Radicava has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Radicava are:
- US6933310
Radicava was authorised for market use on 05 May, 2017.
Radicava is available in solution;intravenous dosage forms.
Radicava can be used as treatment of amyotrophic lateral sclerosis (als).
Drug patent challenges can be filed against Radicava from 05 May, 2021.
The generics of Radicava are possible to be released after 05 May, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-144) | May 05, 2024 |
| ODE*(ODE*) | May 05, 2024 |
| New Chemical Entity Exclusivity(NCE) | May 05, 2022 |
| Orphan Drug Exclusivity(ODE) | May 05, 2024 |
Drugs and Companies using EDARAVONE ingredient
NCE-1 date: 05 May, 2021
Market Authorisation Date: 05 May, 2017
Treatment: Treatment of amyotrophic lateral sclerosis (als)
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
RADICAVA family patents
